Bharat Biotech has partnered with GSK to advance the Shigella vaccine altSonflex1-2-3. With strong early trial results and no safety concerns, Bharat Biotech will now lead phase 3 trials, regulatory processes, and manufacturing for use in low-income countries.
The work of the CGT facility will span across multiple things - from boosting immune responses against cancer to ensuring that therapeutic proteins are safely accepted in patients with genetic diseases like haemophilia
Hyderabad: Covid vaccine maker Bharat Biotech International Limited (BBIL), announced that its Covaxin (BBV152), has proven to be safe, well-tolerated, and highly immunogenic in paediatric subjects in phase II/III study. The study has been accepted and published in Lancet Infectious Diseases, a peer reviewed journal. Bharat Biotech had conducted phase II/III, open-label, and multi-centre study […]
Hyderabad: Bharat Biotech International Limited (BBIL), on Thursday announced that BBV152 (Covaxin), its whole-virion inactivated COVID-19 vaccine candidate, has proven to be safe, well-tolerated, and immunogenic in paediatric subjects in phase II/III study. Bharat Biotech had conducted phase II/III, open-label, and multicenter studies to evaluate the safety, reactogenicity, and immunogenicity of Covaxin in healthy children […]
